富祥药业：关于通过美国FDA现场检查的公告

Core Points - Fujian Pharmaceutical Co., Ltd. announced that it underwent an FDA cGMP inspection from August 11 to August 14, 2025 [2] - The inspection covered various GMP systems including quality management, material management, production management, equipment facilities, packaging and labeling, and laboratory control systems [2] - The company received an Establishment Inspection Report (EIR) from the FDA, indicating a successful inspection with a Voluntary Action Indicated (VAI) result [2]